Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease.·~* HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry will not be sufficient for entry.·~* At least one measurable lesion as defined by the RECIST.~* Prior hormonal therapy for metastatic disease is allowed.~* Maximum of one prior chemotherapy regimen or trastuzumab-containing regimen for unresectable, locally recurrent or metastatic disease~* Prior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease.~Exclusion Criteria:~* No prior therapy with capecitabine or oxaliplatin in any setting~* No prior therapy with other platinum compounds·~* No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.·~* No prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.·~* No prior fluoropyrimidine therapy for metastatic disease is allowed.~* Prior adjuvant fluoropyrimidine therapy is allowed if completed \> 12 months from study entry.·~* No symptomatic brain metastasis. ·~* No evidence of serious concomitant systemic disorders incompatible with the study ·~* No peripheral neuropathy ·~* No major surgery within 28 days prior to beginning protocol therapy.·~* Negative pregnancy test·~* No current breastfeeding·~* No malabsorption syndrome·~* No evidence of serious concomitant systemic disorders incompatible with the study·~* Patients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.

Based on this trial design, predict the completion outcome and termination type (if applicable).